Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Chronic myeloid leukemia--update].

A Tobler1, M Solenthaler

  • 1Hämatologisches Zentrallabor, Inselspital, Universität Bern. andreas.tobler@insel.ch

Therapeutische Umschau. Revue Therapeutique
|March 17, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10.

Leukemia·2011
Same author

The anti-apoptotic gene BCL2A1 is a novel transcriptional target of PU.1.

Leukemia·2010
Same author

Purity and recovery of the CD34+ cell fraction, obtained by the CEPRATE selection system from PBSC collections, can be augmented by meticulous washing steps.

Cytotherapy·2009
Same author

Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98).

Leukemia & lymphoma·2009
Same author

DAPK2 is a novel E2F1/KLF6 target gene involved in their proapoptotic function.

Oncogene·2008
Same author

The hDMP1 tumor suppressor is a new WT1 target in myeloid leukemias.

Leukemia·2007
Same journal

[Multimodal Cardiac Imaging: New Developments for Clinical Practice].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Coronary angiography: From cardiac catheterization to advanced interventional cardiovascular imaging].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Athlete's heart: role of cardiac imaging in the prevention of sudden cardiac death].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Multimodal imaging in cardiac amyloidosis and cardiac sarcoidosis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Inflammatory Heart Disease: The Role of Multimodality Cardiac Imaging in Myocarditis and Pericarditis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

State-of-the-Art Cardiac Imaging

Therapeutische Umschau. Revue therapeutique·2026
See all related articles

Chronic myeloid leukemia (CML) is a stem cell disorder characterized by the Philadelphia chromosome. New treatments, like Imatinib, offer promising therapeutic avenues for CML patients.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Context:

  • Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm originating from clonal hematopoietic stem cells.
  • The Philadelphia chromosome, a result of the t(9;22) translocation, is the defining genetic hallmark of CML.
  • This translocation fuses the ABL protooncogene with the BCR gene, creating the BCR-ABL fusion gene.

Purpose:

  • To review current knowledge of CML treatment options.
  • To highlight the impact of tyrosine kinase inhibitors, particularly Imatinib, in CML therapy.

Summary:

  • CML is characterized by the BCR-ABL fusion gene, leading to uncontrolled tyrosine kinase activity and malignant transformation.
  • Diagnosis involves peripheral blood smear, bone marrow examination, and detection of the Philadelphia chromosome and BCR-ABL transcript.

Related Experiment Videos

  • Recent advancements have introduced novel therapeutic strategies, complicating treatment choices.

    • Impact:

    • Imatinib represents a significant breakthrough, offering a highly effective targeted therapy for CML.
    • The advent of tyrosine kinase inhibitors has transformed CML management, improving patient outcomes.
    • Continued research into CML pathogenesis and treatment is crucial for further therapeutic advancements.